
    
      Concomitantly to the marketing authorization applications for cobimetinib and vemurafenib to
      European Medicines Agency (EMA) and United States Food and Drug Administration (USFDA) in
      2014, a French TAU program was initiated in February 2015. This study will enroll
      participants under this program.
    
  